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a b  s  t  r a  c t
Objective: To  assess the  monetary  savings resulting  from  a  pharmacist intervention on the  appropriate-
ness  of prescribed drugs in community-dwelling  polymedicated  (≥8  drugs)  elderly  people  (≥70  years).
Method:  An evaluation of pharmaceutical  expenditure  reduction was performed  within  a randomised,
multicentre clinical trial. The  study  intervention  consisted  of a pharmacist  evaluation of all  drugs
prescribed  to each  patient  using  the  “Good Palliative-Geriatric  Practice” algorithm  and the  “Screening  Tool
of Older  Persons  Prescriptions/Screening  Tool  to Alert doctors  to  Right Treatment” criteria (STOPP/START).
The control  group  followed  the  routine  standard  of care.  A  time  horizon  of one  year was considered and
cost elements  included  human  resources and  drug  expenditure.
Results:  490 patients (245 in each group)  were  analysed. Both groups  experienced  a decrease  in drug
expenditure  12 months  after  the  study started,  but  this decrease  was  significantly  higher in the  inter-
vention  group than  in the  control group  (−14.3% vs. −  7.7%; p  =  0.041). Total  annual  drug  expenditure
decreased 233.75 D  /patient  (95% confidence  interval  [95%CI]:  169.83-297.67)  in the intervention group
and 169.40  D /patient (95%CI:  103.37-235.43)  in the  control  group over a  one-year period,  indicating that
64.30 D  would  be  the drug  expenditure  savings per patient a year attributable  to the  study  intervention.
The  estimated  return  per  Euro  invested  in the  programme would  be  2.38  D  per patient a  year  on average.
Conclusions: The study intervention  is a cost-effective  alternative  to standard care  that  could generate  a
positive  return of investment.
© 2017 SESPAS. Published by  Elsevier  España,  S.L.U. This is an open  access article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Reducción  del  gasto  farmacéutico  mediante  una  intervención  de  adecuación  de






Atención primaria de  salud
Costes de medicamentos
r  e  s u  m e  n
Objetivo: Evaluar  los ahorros monetarios resultantes de la intervención  de  un  farmacéutico  orientada  a
mejorar  la adecuación de  los fármacos  prescritos en ancianos (≥70 años)  polimedicados  (≥8 medicamen-
tos)  de  la  comunidad.
Método: Se evaluó  la reducción del gasto  farmacéutico  en  el  marco de  un  ensayo clínico aleatorizado  y
multicéntrico. La  intervención  del  estudio  consistió  en  una  evaluación de  todos  los  fármacos  prescritos
a  cada  paciente utilizando  el  algoritmo  Good  Palliative-Geriatric  Practice  y  los criterios Screening  Tool
of Older  Persons  Prescriptions/Screening  Tool to  Alert doctors to  Right  Treatment  (STOPP/START).  El grupo
control siguió la práctica  clínica  habitual. Se consideró  un horizonte temporal  de  un año y  los elementos
de  costes  incluyeron  los recursos  humanos  y  el gasto  en  medicamentos.
Resultados:  Se analizaron  490 pacientes (245  por grupo). La disminución  del gasto  farmacéutico  a  los
12  meses  fue  significativamente  mayor  en  el  grupo de  intervención  que  en  el grupo  control (−14,3%
vs.  − 7,7%; p =  0,041).  El  gasto  anual  en  medicamentos  disminuyó  233,75 D  por paciente  (intervalo de
confianza  del  95%  [IC95%]: 169,83-297,67)  en el grupo de intervención  y  169,40  D por  paciente  (IC95%:
103,37-235,43)  en el  grupo control, indicando  un  ahorro farmacéutico  de  64,30  D por paciente/año
atribuible  a la intervención  del  estudio.  Se ha estimado  un retorno  de  2,38  D por  cada euro  invertido
en  el  programa.
∗ Corresponding author.
E-mail address: mserra@csdm.cat (M.  Serra-Prat).
https://doi.org/10.1016/j.gaceta.2017.09.002
0213-9111/© 2017 SESPAS. Published by  Elsevier España, S.L.U. This is  an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Conclusiones:  La intervención  en estudio  es una alternativa  rentable a  la atención estándar,  que podría
generar  un  retorno positivo de la  inversión.
© 2017  SESPAS. Publicado por  Elsevier  España, S.L.U. Este  es  un  artı́culo Open  Access  bajo  la  licencia  CC
BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Population ageing has led  to an increase in  the prevalence
of chronic diseases and in  the use of health resources including
medication. People over 65 years, which have a  high prevalence
of chronic diseases and are often treated with multiple drugs,1
represent 17% of the current Spanish population and are respon-
sible of 70% of  pharmaceutical expenditure.2 Moreover, in  the last
years, pharmaceutical expenditure has growth much more than the
gross domestic product in  most European countries, threatening
the sustainability of public health care systems.3 On the other hand,
potentially inappropriate prescribing (PIP) comprises a number
of suboptimal prescribing practices, including inappropriate dose
or duration of medication, drug-drug interactions, drug-disease
interactions, and use of medications that have a  significant risk
of an adverse drug event.4,5 PIP has been found to be  frequent
in elderly population and associated with morbidity, adverse drug
events, hospitalizations, and health care expenditures.6,7 For this
reason, strategies aimed to improve the quality and safety of pre-
scription in the elderly population can generate substantial health
and economic benefits.8,9 Several criteria and algorithms have
been developed to reduce PIP. One of the most used criteria is
the  Screening Tool of Older Persons Prescriptions/Screening Tool
to Alert doctors to  Right Treatment (STOPP/START).10 Likewise,
an algorithm used to enable more rational and appropriate use
of medication in  elderly people is  the Good Palliative-Geriatric
Practice (GP-GP).11 Some authors have assessed the safety and
effectiveness of interventions using these tools. Improvements in
drug appropriateness and reduction in  number of medications
have been reported.12,13 Additionally, strategies including a  clini-
cal pharmacist can help decrease PIP and optimize patient therapy,
resulting in better clinical outcomes.14 However, limited evidence
exists about economic evaluations of these interventions.15,16 The
objective of the present study was to assess the economic impact
in drug expenditure of a  pharmacist intervention on prescriptions
to community-dwelling polymedicated elderly people.
Method
Clinical trial design
A randomized, open-label, multicenter, parallel-arm clinical
trial was conducted in seven primary care centers in the city of
Mataró and Argentona (Barcelona, Spain) (122,905 and 11,718
inhabitants respectively, with 13,290 and 1,194 aged 70 years and
over, respectively) to assess the effect of a pharmacist interven-
tion on the appropriateness of prescribed drugs. Details of this
study were published elsewhere.17 In brief, the study population
included a randomly selected sample of community-dwelling (non-
institutionalized) elderly people aged 70 years and older, receiving
eight or more drugs. Recruitment took place from February and
May  2012 and participants were pre-selected from the primary care
database and randomized with allocated concealment to  one of the
two study arms. The intervention, which took place no more than
a month after the recruitment visit, included a  trained and expe-
rienced clinical pharmacist evaluating all drugs prescribed to each
patient using the GP-GP algorithm and basing their decision about
appropriateness on the STOPP/START criteria. The pharmacist
discussed recommendations for each drug with the patient’s
physician on a  face-to-face visit in  order to  come up  with a  final set
of recommendations (stop, start or change medication or  dosage).
Finally, these recommendations were discussed with the patient,
and a  final decision was agreed by physicians and their patients in
a  face-to-face routine visit. A safety control visit was planned one
month later. All  changes in prescribed medication were registered
in  the electronic clinical notes and in the study’s record form.
The control group received usual clinical practice. Overall, 503
patients were recruited; 251 in the control group and 252 in the
intervention group, in which 2709 drugs were evaluated. The study
protocol was  approved by the local ethical committee (CEIC 05/12)
and all participants gave their consent by writing before inclusion.
Cost elements considered
We aimed to assess the reduction in pharmaceutical expendi-
ture alongside the clinical trial due to the pharmacist intervention
in primary care  in  relation to the routine clinical practice (stan-
dard of care by the general practitioner), following the ISPOR Good
Research Practices report for reporting economic evaluation along-
side clinical trials.18 We have considered a time horizon of  one year
following intervention.
Cost elements considered in  the study included particularly
the use human resources and consumption of drugs. In relation
to  human resources, it was  estimated that the study interven-
tion required a  mean of 30 minutes of a  pharmacist per patient
(drug evaluation and discussion with physician) and 20 minutes
of a  physician per patient (discussion with pharmacist and an
additional visit with the patient). Monetary valuation of  time was
possible using salary data available through the 2012 collective
labor agreement (Catalan Health Service). The cost per hour, for
both physicians and pharmacists, was 32.44 D  /hour which included
social security contributions but not  structural costs. Drug prices,
number of dispensed prescriptions, number of “generic drugs” and
number of “new drugs” were obtained from the administrative
pharmacy database of the Catalan Health Service. “New drugs”
are considered drugs commercialized over the last five years and
qualified with category C (most suitable therapeutic alternatives
exist) or  D (alternative therapeutic comparative information is not
conclusive) by the Catalan Health Service. Only dispensed medica-
tion costs were considered, so real cost in drug expenditure was
contemplated. The return of investment of the study intervention
has been calculated dividing the savings in drug expenditure by the
cost of the intervention.
Data analysis
A sensitivity analysis was  performed based on three theoretical
scenarios, the first being the basal scenario (30 minutes pharmacist
and 20 minutes physician time), the second being a  rather more
optimistic one (20 minutes pharmacist and 15 minutes physician),
and a third one labeled as conservative scenario (40 minutes phar-
macist and 30 minutes physician per patient). Among recruited
patients, 13 (2.58%) died during the 12 months follow-up (six
in the control group and seven in  the intervention group), and
were excluded from the cost analysis. The number of dispensed
drugs in the 12 months before the intervention was also obtained
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using the same data sources. The difference between study groups
in drug consumption 12 months before and 12 months after
the intervention was also computed. Continuous variables (total
drug expenditure 12 months after intervention, incremental drug
expenditure 12 months before versus after intervention, total
number of recipes 12 months after intervention and incremental
number of recipes 12 months before versus after intervention) were
described using means or medians (in case of non-normal distri-
bution) and standard deviations. Basal and follow up comparisons
between groups were tested by  the t-test (for variables with nor-
mal  distribution) or the Mann Whitney U test (for variables without
normal distribution). Statistical significance was established at a
p value < 0.05.
To estimate the sample size, the main outcome variable was
the pharmaceutical expenditure 1 year before and 1 year after the
study intervention (paired data). For  an alpha risk of 0.05 and a  beta
risk of 0.2 (two-tailed tests), it was estimated that 81 subjects were
required to detect a  difference equal to or greater than 250 D  in
pharmaceutical expenditure, assuming a  standard deviation (SD)
of 800 D .
Results
After excluding patients who died (n =  13), 245 patients were
recruited to control group (78.7 years, SD: 5.5; 57.9% women) and
245 to intervention group (79.1 years, SD: 5.4; 61.6% women). No
statistically significant differences were observed between the two
groups in the number of drug prescriptions and drug expenditure
during the 12 months before pharmacist intervention, indicating
that both groups were originally comparable. We observed, how-
ever, statistically significant differences in drug expenditure and
in the number of  prescriptions during the 12 months after inter-
vention. As shown in Table 1,  although both  groups experienced a
decrease in drug expenditure 12 months after the study started,
this decrease was significantly higher in the intervention group
than in the control group. Similarly, the rise in  generic drug
prescriptions was significantly greater in the intervention group.
Table 1 also reports on total cost and total number of prescriptions
before and after the pharmacist intervention. It shows a signifi-
cant reduction for both groups in  total costs, in the total number of
Figure 1. Evolution of median of drug expenditure (D ) per patient 12 months before
and 12 months after the intervention.
prescriptions, and a  significant increase in  both groups in the per-
centage of generic drugs prescribed. We also observed a  significant
increase in the number of new drug prescribed in the control
group. Total annual drug expenditure in  the intervention group
decreased from 317,520.00 D  (pre-intervention) to 260,263.00 D
(post-intervention), representing 233.75 D  (95% confidence inter-
val [95%CI]: 169.83-297.67) saved per patient (1,296.00 D  /patient
pre vs.  1,062.30 D /patient post). Similarly, total annual drug expen-
diture in the control group decreased from 338,271.00 D to
296,768.00 D ,  which results in  169.40 D  (95%CI: 103.37-235.43)
saved per patient over one-year period (1,380.70 D  /patient pre vs.
1,211.30 D /patient post). The resulting incremental drug expendi-
ture of standard care over pharmacist intervention is 64.30 D  per
patient each year. In other words, 64.30 D  would be the cost savings
per patient a  year attributable to the study intervention.
Table  1
Prescription patterns and associated annual costs/expenditures per patient before and after the pharmacist intervention.
Intervention group




Mean (SD) 95%CI Mean (SD) 95%CI
12 months before intervention





Annual number of prescriptions/patient 127.9 (43.6) (122.4-133.4) 134.3 (50.4) (128.0-140.6) 0.228a
Prescriptions in generic drugs (%) 39.1 (15.8) (37.1-41.1) 40.6 (16.4) (38.5-42.65) 0.299b
Prescriptions in new drugs (%)  0.9 (2.7) (0.6-1.2) 0.7 (2.3) (0.4-1.0) 0.972a
12 months after intervention





Annual number of prescriptions/patient 109.1 (40.6) (104.0-114.2) 118.5 (43.1) (113.1-123.9) 0.013b
Prescriptions in generic drugs (%) 46.3 (17.1) (44.2-48.4) 45.5 (17.2) (43.3-47.6) 0.585a
Prescriptions in new drugs (%)  1.1 (3.2) (0.7-1.5) 1.4 (3.0) (1.0-1.8) 0.064a
Before-after differences
Reduction in drug expenditure (D ) 233.75 (510.46) (169.83-297.67) 169.40 (527.35) (103.37-235.43) 0.171a
Reduction in drug expenditure (%)  14.3 (40.8) (19.4-9.2) 7.7 (42.7) (13.0-2.35) 0.041a
Reduction in number of prescriptions (%)  12.5 (22.0) (15,2-9,75) 8.9 (23.4) (11.8-2.3) 0.091b
Increase in generic drug prescriptions (%)  7.4 (11.7) (5.9-8.8) 5.1 (10.6) (3.8-6.4) 0.025b
Increase in new drug prescriptions (%) 0.2 (3.0) (−0.2-0.5) 0.7 (2.4) (0.4-1.0) 0.007a
95%CI: 95% confidence interval; SD:  standard deviation.
a Mann Whitney U test.
b t-test.
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Figure 2. Evolution of median of prescriptions per patient 12 months before and
12  months after the intervention.
Figure 3. Evolution of percentage of generic drugs per patient 12 months before
and  12 months after the intervention.
Figures 1 and 2 displays the monthly evolution of median
drug expenditure and median number of prescriptions during 12
months pre-intervention and 12 months post-intervention for both
groups. Further, the higher percentage of generic drugs prescribed
in the intervention group remained largely unchanged throughout
the one-year follow-up (Fig.  3). Finally, as regard the prescription of
new drugs (Fig. 4), it is  the standard care group that shows a  rather
more ascendant pattern, particularly over the last 4 months in  the
study.
Table 2  presents the additional costs and savings under three
scenarios. The average annual saving resulting from the study inter-
vention is 37.57 D  per patient a year. According to the sensitivity
analysis performed, annual savings per patient range from 45.68
D  (optimistic scenario) to 26.75 D  per patient (conservative sce-
nario). If we were to  estimate the return on investment of the study
intervention, dividing cost savings (64.30 D  ) by annual cost of inter-
vention for each scenario, we  would argue that for 1 D invested in
Figure 4. Evolution of percentage of new drugs per patient 12 months before and
12  months after the intervention.
the program we would be saving an average of 2.38 D  per patient
a year (ranging from 1.70 D  to 3.40 D ).
Discussion
Our study reveals that a one-time pharmacist intervention in
primary care allows for a 12 months accumulated reduction in  total
drug prescription and expenditure in community-dwelling poly-
medicated elderly people. It  also shows an increase in  the number
of prescribed generic drug and a  reduction in  the number of  pres-
cribed “new drugs”. Since savings in  drug expenditure are greater
than costs derived from the intervention, the pharmacist interven-
tion can be a cost-effective alternative to standard of care  rendering
a positive return on investment (2.38 D  ) per euro.
Our results are consistent with other findings from previous
studies evaluating the economic impact of pharmacist inter-
ventions. In a series of systematic reviews conducted for the
American College of Clinical Pharmacy, the economic value of
clinical pharmacist services was  summarized and evaluated. The
first review, conducted by Schumock et al.,19 evaluated articles
published from 1996-2000. They concluded that for every $1
invested in clinical pharmacy services, $4  was achieved in reduced
costs or other economic benefits. A  review by Pérez et al.,20
that included articles published between 2001-2005, showed sim-
ilar results. The most recent published review on the topic21
incorporated fewer number of studies, published between 2006-
2010, and could not provide a benefit/cost ratio as previous
reviews did. One important difference between our study and
other published studies included in these reviews is that the latter
focused more on specific clinical conditions. Brennan et al. demon-
strated a return on investment ratio of 3:1 using an integrated
pharmacy program to improve medication prescription and adher-
ence rates in diabetes patients.22 Pharmaceutical interventions
have also proven to be cost-effective in pathologies such HIV,23
depression24 or hypertension.25 Despite these pieces of  evidence,
there are very few studies that focused on the economic evalua-
tion of a pharmacist intervention that aim at reducing potentially
inappropriate prescriptions and at improving drug appropriate-
ness in community-dwelling polymedicated elderly people. When
published, such studies showed very modest savings regarding
medication costs with no statistical significance.26
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Table 2
Sensitivity analysis of the annual benefits per  patient considering three cost scenarios.
Scenario Scenario 0, basal
(30 min  pharmacist+ 20 min
physician)
Scenario 1, optimistic
(20 min  pharmacist+ 15 min
physician)
Scenario 2,  conservative
(40 min  pharmacist+ 30 min
physician)
Intervention Control Intervention Control Intervention Control
Annual additional cost of intervention per
patienta
27.03 D 0 D 18.92 D 0  D 37.85 D 0  D
Difference in benefit per  patient between
groups (net savings)
− 37.57 D −  45.68 D  − 26.75 D
Return  of investmentb 2.38 D  3.40 D 1.70D
a Additional cost of intervention per  patient results from adding the respective minutes of pharmacist and primary care  physician at a cost of 32,44 D per hour.
b Average savings for every euro invested in the program (obtained dividing cost savings (64,30 D ) by  annual cost of intervention for each scenario).
Monthly evolution of median cost, median prescriptions per
patient and percentage of generic drugs showed a somewhat
parallel evolution on control and intervention groups indicating
that the initial gap between both groups generated by the pharma-
cist intervention had a long-lasting effect on  both variables. This
effect appears to be slightly diluted one year after the intervention,
and perhaps indicates that another pharmaceutical intervention
should be done as reinforcement. On the other hand, “new drugs”
showed an increase in  prescription over the last 4 months in the
study, pointing to  a greater penetration of new products as thera-
peutic options in this group.
Although a significant reduction in drug prescription and expen-
ditures was observed resulting from the intervention, it is of
relevance to report that the control group also experienced a signifi-
cant reduction in drug expenditure itself during the follow-up study
period. This fact can be partially attributed to the study design,
which was an open-label randomized clinical trial with possible
intervention-to-control contagion. The prescribing physicians who
received recommendations from the pharmacist regarding patients
in the intervention group also visited patients in the control group.
Consequently, the control group have indirectly benefited from the
intervention, possibly diluting the true effect of the intervention.
Moreover, the decrease in drug prescription in the control group
may  also be explained by  other measures put forward by the Cata-
lan Health Service to control drug expenditure in  the primary care
setting and by other important state control measures such as the
Royal Decree-Law 16/2012, which introduced the co-payment sys-
tem for outpatient pharmaceutical services and the exclusion of
more than 400 products from public funding.
The reduction in total drug expenditure is largely a  conse-
quence of a decrease in the number of drugs prescribed (drug
discontinuations), which accounts for 9.2% of total initial prescrip-
tions. In addition, dose adjustments accounted for 6.9% and drug
substitutions for 3.1% of initial prescriptions17.  The use of generic
drugs had a limited impact in drug cost savings since the Spanish
drug regulation does not  allow for differences in  publicly financed
prices between generic and non-generic drugs. Finally, it should be
noted that although the prescription of new drugs is  only a small
percentage of overall drug prescription, the control group shows a
more than three-fold increase in  this respect when compared to the
intervention group. Given the very high price of these new drugs,
small differences in prescription frequency may  have a  relevant
economic impact.
Probably, the main strength of the study is  its controlled and
randomized experimental design. There are a number of advan-
tages of performing economic studies as part of an on-going clinical
trial.27 Among other benefits, it is argued that since economic
evaluation largely depends upon the quality of the data generated,
clinical trials are an efficient setting for economic analyses. Both
the quality of the data and the greater control over potential
sources of bias favor clinical trials. However, the literature also
outlines some limitations, the most relevant to  our  study being
the generalization of the economic impact of the intervention in
real-world practice. To overcome this limitation, we have selected
a  comparator that represents the most realistic choice in  real prac-
tice. Other study limitations include: a) the intervention-to-control
contagion, which may  dilute the effect of the intervention; b) the
exclusion of deaths from the analysis, which may carry an under-
estimation of total drug expenditure but do not alter inter-group
comparisons because of the balanced number of deaths between
groups; and c) cost elements considered are only cost in  drug
consumption and direct costs in  human resources (time invested
was a theoretical estimation), therefore more economic impact
studies and full economic evaluations are required.
In  summary, the present study shows that  the intervention of
a clinical pharmacist in the primary care setting evaluating all
medication in polymedicated community-dwelling elderly sub-
jects is responsible for a  reduction of approximately 7%  in drug
expenditure. Such a community intervention may be a cost saving
alternative with a  possible positive return on investment.
What is known about the topic?
Potentially inappropriate prescribing has been found to
be frequent in elderly population and associated with mor-
bidity, adverse drug events, hospitalizations, and health care
expenditures. Several criteria and algorithms have been devel-
oped to reduce it. However, limited evidence exists about
economic evaluations of  these interventions.
What does this study add to the literature?
The intervention of  a clinical pharmacist in the primary care
setting evaluating all  medication in polymedicated elderly sub-
jects is responsible for a reduction of approximately 7% in total
drug expenditure (a mean reduction of  64  D per patient a year).
Such a community intervention is a cost saving alternative with
a positive return on investment.
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